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A prerequisite for cancer cells to expand and survive is the devel-
opment of strategies for escaping surveillance by the immune
system. The Fas/Fas-ligand-system is an important mediator of T
cell-and natural killer (NK) cell cytotoxicity. Fas-ligand, a mole-
cule that belongs to the TNF-ligand superfamily (along with TNF,
LTa,-b, CD27L, CD30L, CD40L, 4-IBB/CD137, OX40L,
TWEAK and TRAIL) is expressed normally on activated NK and
T cells (Gruss, 1996; Chicheportiche et al, 1997). It can induce
apoptosis in Fas-expressing cells including immune cells.
Thereby, Fas-ligand can control various entities of immune regula-
tion including immune response termination (e.g. through periph-
eral deletion of activated T cells), tolerance acquisition and
immune privilege (Kagi et al, 1994; Arase et al, 1995; Nagata,
1997). Fas (APO-1, CD95), the receptor for Fas ligand belongs to
the TNF-receptor superfamily and signals cell death after binding
with its specific ligand. It is similar in action to other members of
this receptor superfamily like TNF-R1, TNF-R2, TRAIL-R1,
TRAIL-R2 and TRAMP (Schulze-Osthoff et al, 1998). Cell
surface Fas is anchored by a single membrane-spanning domain
and is widely expressed on normal and malignant cells (Nagata,
1997). Both Fas and Fas-ligand exist in a membrane bound and a
soluble form (Cascino et al, 1995; Liu et al, 1995; Dhein et al,
1995). Soluble Fas (sFas) is generated by alternative mRNA
splicing events and to date 4 isoforms of sFas have been described
(Cascino et al, 1995; Liu et al, 1995). The most predominant sFas
isoform results from the deletion of exon 6 encoding the last 5
amino acid residues of the extracellular domain and 16 of 17
amino acids in the transmembrane domain (Cascino et al, 1995).
This isoform has been identified in the supernatants of activated
human lymphocytes, several tumour cell lines (Cheng et al, 1994;
Natoli et al, 1995; Owen-Schaupp et al, 1995) and in patients with
solid tumours (Midis et al, 1996). The soluble form of Fas-ligand
is generated by cleavage of a 26 kD TNF-homologous portion of
membrane-bound Fas-ligand by a metalloprotease (Tanaka et al,
1995). 
The physiological importance of the Fas system was originally
thought to be confined to the immune system. Recent evidence
demonstrates expression of Fas-ligand not only on NK and T cells
(Suda et al, 1993) but also on a variety of non-immunological
(Runic et al, 1996; Bamberger et al, 1997; Nagata, 1997) and
malignant cells. There it has been demonstrated to be a major
factor in the Fas/Fas-ligand based interactions between cytotoxic
T lymphocytes and cancer cells in immune escape (Tanaka et al,
1995; Griffith et al, 1996; O’Connell et al, 1996; Runic et al, 1996;
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Summary Mechanisms of resistance against Fas-mediated cell killing have been reported in different malignancies. However, the biological
response of immune escape mechanisms might depend on malignant transformation of cancer cells. In this study we investigated different
mechanisms of immune escape in 2 well-differentiated low-grade (RT4 and RT112) and 2 poorly differentiated high-grade (T24 and TCCSUP)
bladder cancer cell lines. Fas, the receptor of Fas-ligand, is expressed and shedded by human transitional bladder carcinoma cell lines RT4,
RT112, T24 and TCCSUP. Cytotoxicity and apoptosis assays demonstrate that in spite of the Fas expression, poorly differentiated T24 and
TCCSUP cells are insensitive towards either recombinant Fas-ligand or agonistic apoptosis-inducing monoclonal antibody against Fas. In
poorly differentiated T24 and TCCSUP cell lines we were able to detect marked Fas-ligand protein by flow cytometry and Western blot
analysis. In grade 1 RT4 and RT112 cells only minor expression of Fas-ligand possibly because of proteinase action. Fas-ligand mRNA
translation or post-translational processing seems to be regulated differentially in the cancer cell lines depending on malignant transformation.
In co-culture experiments we show that poorly differentiated cells can induce apoptosis and cell death in Jurkat cells and activated peripheral
blood mononuclear cells. This in vitro study suggests that bladder cancer cells can take advantage of different mechanisms of immune
evasion and become more competent in avoiding immune surveillance during transformation to higher-grade malignant disease. © 2001
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Strand et al, 1996; Bamberger et al, 1997; Niehans et al, 1997;
Niehans et al, 1997; Shiraki et al, 1997; Ding et al, 1998; Gratas
et al, 1998; Ungefroren et al, 1998; Bernstorff et al, 1999). Further
strategies of immune escape developed by cancer cells have been
proposed. For example, effective utilization of the Fas/Fas-ligand
system would also require resistance to Fas-ligand induced signal
transduction (Ungefroren et al, 1998). In addition, circulating
isoforms of Fas and Fas-ligand do prevent recognition of patho-
logical, i.e. malignant cells by the immune system (Cheng et al,
1994; Hahne et al, 1996; Mitsiades et al, 1998). 
In this study we investigated Fas and Fas-ligand expression as
well as their sensitivity to Fas-mediated apoptosis in 4 bladder
cancer cell lines of different malignant transformation. The
possible importance of soluble Fas and Fas-ligand in immune
escape was examined by assessing the production of these soluble
molecules in the different cancer cell lines. Furthermore the apop-
totic potential of (Fas-ligand expressing) bladder cancer cells
towards a transformed T cell clone (Jurkat) and stimulated periph-
eral blood mononuclear cells (PBMC) were analysed by co-culture
experiments. 
MATERIAL AND METHODS 
Tumur cell lines and culture conditions 
The human transitional cell carcinoma cell lines RT4 (grade 1),
RT112 (grade 1), T24 (grade 3) and TCCSUP (grade 4) were
obtained from ATCC (Rockville, MD). All tumour cell lines were
maintained as adherent cells at 37˚C in 5% CO2 in humidified
atmosphere in RPMI 1640 culture medium (Biochrom, Berlin)
supplemented with 10% heat-inactivated fetal calf serum (FCS),
1% nonessential amino acids, 2 mM L-glutamine, 100 units ml–1
penicillin G, 100 mg ml–1 streptomycin and a vitamin solution
(Gibco BRL, Life Technologies Inc, Frederick, MD). For experi-
ments, 1 ´ 106 tumour cells were seeded in 25 cm2 culture flasks
(Costar, Cambridge) and incubated for 48 h to allow maximum
confluence thus providing optimal cell–cell contact. Cells were
routinely subcultured by trypsination (0.05% Trypsin, 1mM
EDTA) (Gibco BRL). 
Antibodies 
Inducing anti-Fas mAb (Mouse IgGl, clone DX2) Calbiochem,
Cambridge, FITC labeled anti-Fas mAb (Mouse IgGlk, clone
DX2) Pharmingen, San Diego, CA; anti-Fas-ligand mAb (Mouse
IgGl, clone NOK-1) Pharmingen, San Diego, CA and anti-Fas-
ligand mAb (Mouse IgG1, clone H11) Alexis, San Diego, CA
were used in the study. Unconjugated IgG1 mAb (Cymbus, Hants,
UK) and FITC/PE-conjugated IgG1 mAb (Dako, Denmark) were
used as isotype controls. 
Flow cytometric analysis of cell surface Fas and Fas-
ligand 
The expression of Fas and Fas-ligand on tumour cells was deter-
mined by flow cytometry in non-permeabilized cells. Briefly, cells
were incubated with matrixmetalloproteinase inhibitor KB8301
(Pharmingen) in normal medium for 24 h and harvested by rapid
trypsination to achieve best detachment of cells from the culture
flask without damage to membrane integrity (after removal of the
culture medium, trypsin was applied for 20 s only, then removed
again and cells were incubated for another 5 min without trypsin
or medium before adding PBS for washing of cells). KB8301 is
added to the cell culture system to increase the levels of mFas-
ligand by blocking Fas-ligand cleavage (Kayagaki et al, 1995). 3 ´
105 cells were washed in cold calcium- and magnesium-free PBS
and centrifuged at 400 g for 10 min. Thereafter, the pellet was
resuspended in 50 ml FACS buffer (PBS, 5% fetal calf serum,
0.02% sodium citrate) on ice, containing 6 ml of FITC labelled
anti-Fas or anti-Fas-ligand-mAb (Clone NOK-1, Pharmingen or
clone H-11, Alexis), or 5 ml of FITC conjugated irrelevant mouse
IgGl mAb serving as isotype control. After washing in PBS once
more, the cells were immediately analysed using a FACS can flow
cytometer (Becton Dickinson, San Diego, CA). A minimum of
10 000 events were acquired for each sample. 
Western blot for Fas-ligand 
Cells were trypsinized, washed with ice-cold PBS and lysed in
lysis buffer (10 mM Tris-Hcl, pH 7.4, 10 mM magnesium chlo-
ride, 5 mM EDTA and 1% Triton-X-100) supplemented with
1 mM PMSF (protease inhibitor phenylmethylsulfonyl fluoride)
(Boehringer), 200 mg aprotinin (Sigma) and 10 mM leupeptin
(Boehringer). Samples containing 100 mg of protein in loading
buffer (0.312 M Tris-HC1, pH 6.8, 0.5% bromophenol blue, 10%
sodium dodecyl sulfate (SDS), 25% glycerol, 100 mM dithioery-
thriol) were boiled for 10 min, subjected to SDS-PAGE (12.5%)
and transferred to a nitrocellulose transfer membrane (Milipore).
Membranes were blocked with 5% non fat dry milk in TBS (50
mM Tris, pH 7.5, 150 mM sodium chloride) and incubated
overnight at 4 °C with anti-Fas-ligand-mAb (Alexis, Germany)
diluted in 2% TBS Tween 20. Immunological complexes were
visualized by enhanced chemiluminiscence (Pierce, Europe BV)
using horseradish peroxidase-conjugated goat-antimouse IgG
(Dako, Denmark). 
RT-PCR detection of Fas-ligand 
RNA isolation and reverse transcriptase (RT) 
Total RNA of 5 ´ 106 cells was isolated using a RNA isolation kit
based on a modified salt precipitation procedure according to the
manufacturer’s instructions (Purescript, Gentra Systems Inc,
Minneapolis, MS). RNA was precipitated in an equal volume of 2-
propanol at-80˚C for 15 min. Precipitates were pelleted at 10 000 g
for 15 min at 4˚C and washed in 75% ethanol. Air-dried pellets
were resuspended in RNase-free water. A 50 ml DNase digestion
reaction with 25 mM Tris-HCl pH 7.2, 5 mM MgCl2, 0.1 mM
EDTA pH 8.0,10 units of DNase, RNase free (Boehringer
Mannheim, Germany) and 40 units of RNasin (Promega, Madison,
USA) was incubated at 37˚C for 30 min to avoid any DNA conta-
mination of the samples. Total RNA was isolated again and air-
dried pellets were resuspended in 50 ml RNase-free water and
frozen at –80˚C overnight. The concentration of RNA was esti-
mated by spectrophotometry (OD 260). cDNA synthesis was
performed using a MMLV RNase H reverse transcriptase
(SuperScript II, Gibco BRL, Life Technologies Inc, Frederick,
MA) according to the manufacturer’s instructions. Briefly, 1 mg of
total RNA template and 1 ml random hexamers (50 mM, Perkin
Elmer, Applied Biosystems Division, Foster City, CA) were
initially heated to 65˚C for 10 min to reduce secondary structure
and quick-chilled on ice. The samples were then incubated for
10 min at 25˚C followed by 60 min at 42˚C with 200 units of1332 FGE Perabo et al 
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Superscript II reverse transcriptase, 500 mM dNTP mix
(Pharmacia Biotech, Uppsala, Sweden), 50 mM Tris-HCL pH 8.3,
75 mM KC1, 3 mM MgCl2, 10 mM dithiotreitol and 20 units of
RNasin in a 20 ml final volume. The reaction was terminated by
heating to 70˚C for 15 min. After 10-fold dilution with DEPC-
treated water, samples were stored at 220˚C for subsequent
analysis. 
Fas-ligand cDNA amplification 
Each 20 ml amplification reaction with 10 mM Tris-HCl pH 8.3,
50 mM KCl, 2 mM MgCl2, 200 mM each dNTP, 250 nM each
Primer and 0.5 units of AmpliTaq Gold (Perkin Elmer) contained
1 ml of diluted cDNA reaction mixture. Amplifications were
carried out using 35 cycles of 94˚C for 30 s, 55˚C for 40s and 72˚C
for 50 s after an initial denaturation of 14 min at 95˚C. The primer
sequences and amplification product size were as follows: sense,
5¢-CAC CTT GGA ATT GTC GTG C-3¢ and antisense, 5¢-CCT
CCA TAT CAG CAG ATC C-3¢ (188 bp). To provide a positive
control for Fas-ligand expression, PBMC were suspended in
RPMI-1640 with 10% autologous serum, stimulated with 5 nM
PMA and 1 mM ionomycin for 3 h, and used to prepare cDNA.
Control reactions without cDNA were carried out in parallel to
ensure that reagents were not contaminated and were consistently
negative. Each amplification was carried out 3 times with similar
results. PCR products were isolated by gel electrophoresis on
1.75% agarose gels and visualized by staining with GelStar (FMC,
Rockland, ME), and their predicted size was verified by compar-
ison to a 100bp ladder (Gibco). Gels were documented with the
Gel Doc 1000 video gel documentation system (Bio Rad
Laboratories, Hercules, CA). 
Soluble Fas and soluble Fas-ligand ELISA 
sFas and sFas-ligand in cell culture supernatants were measured
with commercially available enzyme-linked immunosorbent
assays (ELISA) ((sFas) Endogene, Woburn, MA/(sFas-ligand)
MBL, Naka-ku Nagoya, Japan). In short, a monoclonal antibody
recognizing an epitope of Fas and monoclonal antibodies against 2
different epitopes of Fas-ligand (clones 4H9 and 4A5), respec-
tively were precoated onto the walls of microtiter plates. Standards
and 1:20 diluted samples were introduced into the wells and imme-
diately the corresponding horseradish peroxidase (HRP) con-
jugated antibody was added. Following incubation, unbound
enzyme-conjugated antibodies were removed by washing and
substrate solution was added to the wells. A colored product was
formed in proportion to the amount of Fas and Fas-ligand, respec-
tively in the sample. The reaction was stopped with sulfuric acid
and the absorbance was measured photometrically by an ELISA
reader at 450 nm (SLT, Crailsheim). The concentrations of sFas
and sFas-ligand were calculated by means of a corresponding
standard curve. 
Cytotoxicity assay 
The MTT (Microculture Tetrazolium) assay was used to assess cell
viability after exposure to inducing anti-Fas-mAb or recombinant
human Fas-ligand (Alexis, San Diego, CA). In brief, trypsinized
tumour cells were resuspended in medium at 5 ´ 105 cells ml–1
after verifying cell viability by trypan blue dye exclusion. 100 ml
of cell suspension were distributed into each well of a 96-well flat
bottomed microtitre plate and each plate was incubated for 24 h to
allow adherent cell growth. Following the incubation, the medium
was removed and 200 ml of the different reagent solutions in
complete medium and medium control were distributed into each
well and incubated for 24, 48 and 72 h. After incubation, 20 ml of
the MTT dye working solution (5 mg ml–1) (Sigma Chemical Co,
St Louis, MO), was added and incubated for 4 h. The supernatant
in the wells was decanted and replaced by 200 ml 2-propanol,
supplemented with 0.05N HCl to dissolve the reactive dye. The
absorbance (A) values of each well were read at 550 nm using an
automatic multiwell spectrophotometer (340 ATTC SLT,
Crailsheim). The negative control was used for zeroing the
absorbance. The growth inhibition percentage was calculated
using the background-corrected absorbance as follows: % Growth
Inhibition = [(1-A of experimental well)/A of positive control
well]*100. Each experimental data point represents average values
obtained from 6 replicates, each experiment was performed in
duplicate. 
Assessment of apoptosis by FITC-labelled Annexin-V
and propidiumiodide 
Annexin-V binds to phosphatidylserine (PS), which is exposed to
the outer leaflet of the plasma membrane during early apoptosis
when the membrane integrity is still maintained. To evaluate the
extent and time course of apoptosis after incubating cells with
inducing Fas-mAb or rhFas-ligand, Annexin-V and propidium-
iodide (PI) were used in double stain technique. Cells were coun-
terstained with PI as a vital dye to distinguish between apoptotic
(Annexin V positive, PI negative) and necrotic (Annexin V posi-
tive, PI positive) cells, respectively. Following the procedure
described above, controls and 3 ´ 105 treated cells (all attached
cells and detached cells in supernatant) were resuspended in
200 ml of culture medium without phenolred, incubated with 5 ml
FITC-conjugated Annexin-V and 10 ml PI for 20 min at room
temperature in the dark, and were then immediately analysed
by flow cytometry. A minimum of 10 000 events was acquired for
each sample. 
Co-culture experiments 
Jurkat T leukaemia cells, which express Fas and are sensitive to
Fas-ligand induced apoptosis, were a kind gift of Dr J Wessendorf,
Department of Dermatology, University of Bonn. Jurkat is a Fas-
sensitive cell line of T cell origin that is permanently activated and
has been used as a model for activated T cells, with which it shares
functional similarities. Furthermore, Jurkat are insensitive to TNF-
alpha, another major mediator of apoptotic cell death (Alderson
et al, 1995). Peripheral blood mononuclear cells (PBMC) were
obtained after Ficoll centrifugation of freshly collected blood of
healthy volunteers. PBMC were suspended in RPMI-1640 with
10% autologous serum, stimulated with 5 nM PMA and 1 mM
ionomycin for 3 h. 
Jurkat cells or PBMC (floating in the medium) were co-cultured
with RT4 or T24 bladder cancer cells (growing adherent to the
flask bottom) at different ratios (1:10,1:1, 2.5:1 and 10:1) for 24 h.
As controls, RT4, T24, Jurkat and PBMC were cultured alone
under the same culture conditions. Following co-culture, the
floating Jurkat or PBMC were collected from the culture super-
natant, then the RT4 or T24 were carefully trypsinized and washed
once with PBS. Cells were separately examined for apoptosis by
flowcytometry after Annexin-V/PI staining. Statistical analysis 
Statistical evaluation of the FACS data was done using the
FACScan software, version ‘CellQuest’ (Becton Dickinson). All
experiments were repeated thrice, the results were expressed as the
mean ± SD. Statistical analysis of the MTT assay was determined
by two-tailed unpaired t test. A P value of 0.05 or less was consid-
ered significant. 
RESULTS 
Expression of cell surface Fas 
Flow cytometric analysis of Fas expression was performed on
bladder cancer cell lines RT4, RT112, T24, TCCSUP and Jurkat
cells as well as on non-activated and activated PBMC. As shown
in Figure 1, high Fas expression was found in all the bladder
cancer cell lines studied, as well as in Jurkat and both, activated
and non-activated PBMC. 
Fas-ligand expression in bladder cancer cell lines 
As shown in Figure 2, T24 and TCCSUP cells demonstrated posi-
tive staining with the employed antibodies against Fas-ligand,
whereas RT4 and RT112 cells only expressed minor (if any)
amounts of Fas-ligand. The Fas-ligand antibody from clone H-11
demonstrated a slightly better antigen binding than from clone
NOK-1. Jurkat cells and PMA-stimulated PBMC served as a posi-
tive control and demonstrated Fas-ligand expression as well. Non-
activated PBMC served as negative control (Figure 2). 
For verification of Fas-ligand expression we examined whole
cell lysates from all cell lines. These lysates were subjected to
immunoblotting using the clone H-11 antibody. In T24 and
TCCSUP cell lines a band (Mr 26 000) was observed, consistent
with the size of a previously reported, protealytically processed
form of Fas-ligand (Ungefroren et al, 1998) (Figure 3). Jurkat cells
showed a weak positive band for the Mr 26 000 protein, and RT4
and RT112 did not demonstrate any expression of this band, thus
suggesting the absence of Fas-ligand in the latter cell lines. We did
not succeed in detecting the transmembrane form of the Mr
37 000–40 000 Fas-ligand protein in any cell line. However, the
difficulty in demonstrating the presence of this particular protein
band in immunoblots has been shown in pancreatic carcinoma
(Ungefroren et al, 1998). 
To investigate possible differences in the transcription of the
Fas-ligand gene, RT-PCR was performed on total RNA extracted
from the cell lines. A cDNA fragment of the predicted size (188
bp) could be amplified from all bladder cancer cell lines as well as
from Jurkat (Figure 4), the identity of Fas-ligand cDNA was
confirmed by sequencing (data not shown). 
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Figure 1 Cell surface Fas expression on RT4 (A), RT112 (B), T24 (C), SUP
(D) bladder cancer cells, Jurkat (E) and PBMC (F); thin line: control with
isotype matched irrelevant immunoglobulin, bold line: specific antibody (Fas)
expression. 106 cells were stained with FITC-conjugated Fas-mAb (DX-2) and
FITC-conjugated IgGl as isotype control and examined by flow cytometric
analysis 
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Figure 2 Flow cytometric analysis of Fas-ligand expression on non-
permeabilized human bladder cancer cell lines RT4 (A), RT112 (B), T24 (C),
TCCSUP (D) bladder cancer cells and Jurkat (E) and non-activated PBMC as
positive (F) and negative (G) control cell lines, respectively. Antibody clone
H-11 (bold line) or an irrelevant antibody (IgG1, isotype control) for
determination of unspecific antibody staining (thin line) was used. RT4 and
RT112 express minor Fas-ligand whereas T24, SUP and Jurkat demonstrate
specific antigen expression. Non-activated PBMC as negative control
demonstrates no Fas-ligand expression (isotype and specific antibody
overlaying) Resistance to anti-Fas-mAb and recombinant Fas-
ligand 
Expression of Fas, though necessary, is not predictive of a biolog-
ical response to Fas-ligand binding (Owen-Schaub et al, 1994).
Some monoclonal antibodies (mAb) against Fas-receptor function
as Fas-ligand and can also induce apoptosis (Ogasawara et al,
1993; Nakamura et al, 1997). However, it has recently been
suggested that antibody agonists have limited properties in
inducing apoptosis (Thilenius et al, 1997), therefore we performed
experiments comparing agonistic monoclonal antibody (anti-Fas)
and recombinant human Fas-ligand. The effect of these agents on
cell viability were investigated with the MTT assay. We found that
concentrations of 50 ng ml–1, 500 ng ml–1 and 5000 ng ml–1 of anti-
Fas corresponded to the death-inducing potential of 10 ng ml–1, 50
ng ml–1 and 250 ng ml–1 of recombinant Fas-ligand, respectively
(data not shown). For practical reasons, we therefore used anti-Fas
in further experiments. 
Next, we investigated the effects of anti-Fas treatment on cell
viability (via MTT assay) and apoptosis induction (via Annexin-
V/PI staining) by adding anti-Fas-mAb (1 mg ml–1) to the culture
medium. In the MTT assay, RT4 and RT112 cells showed a
marked 60–70% reduction in cell viability (P < 0.05) after 72 h
treatment with anti-Fas. On the other hand, T24 and TCCSUP
showed only a limited decrease in cell viability of approximately
30–40% (Figure 5). 
Evaluation of apoptosis demonstrated a low spontaneous apop-
totic rate of <20% in untreated cell lines. After exposure to anti-
Fas-mAb the proportion of apoptotic cells increased up 4-fold in
RT4 and RT112 cell lines, whereas in T24 and TCCSUP cell lines,
the increase in apoptosis was significantly less (P < 0.05) (Figure 6). 
Production of sFas and sFas-ligand by bladder cancer
cell lines 
Cell culture supernatants with increasing cell counts from 103–106
cells were analysed by specific ELISAs. Only at a cell count of
>106 cells ml–1 we found a measurable sFas concentration in the
cell lines (Table 1). We could not detect soluble Fas-ligand in
culture supernatants of all cell lines with the employed ELISA kit. 
Interaction of bladder cancer cells with Jurkat and
activated PBMC 
Having demonstrated that high grade malignant bladder cancer
cells like T24 and TCCSUP express Fas-ligand, yet are largely
insensitive to Fas-mediated apoptosis, we wanted to see if the Fas-
ligand is functional, i.e. if bladder cancer cells can induce apop-
tosis in Fas-expressing immune cells like Jurkat or activated
PBMC. On the other hand, RT112 and RT4, not expressing Fas-
ligand, should not be able to induce apoptosis in Jurkat or PBMC.
To address this question, co-culture experiments were used. 
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RT4 RT112 T24 Jurkat TCCSUP
26
Figure 3 Immunoblot analysis of Fas-ligand expression in whole cell lysates
were subjected to PAGE and blotted onto a nitrocellulose membrane. Fas-ligand
in the T24 (lane 3) and TCCSUP (lane 5) cells demonstrate expression of a
Mr 28 000 protein. Jurkat control cells demonstrate weak expression (lane 4),
and no expression of Fas-ligand in RT4 and RT112 cells (lane 1 and 2) 
Figure 4 Bladder cancer cell lines contain Fas-ligand mRNA. Samples of
total RNA (1 mg) were reversely transcribed and subjected to 35 PCR cycles
as described in ‘Materials and Methods’. The amplified products with a size
of 188 bp were electrophoresed through a 1.75% agarose gel and stained
with GelStar. Line 1: Marker, line 2: RT112, line 3: RT4, line 4: T24, line 5:
TCCSUP, line 6: Jurkat, line 7: negative control, line 8: positive control 
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Figure 5 Comparison of cell viability in RT4, RT112, T24 and TCCSUP
cells after 24, 48 and 72 h of incubation time with 1 mg ml–1 inducing anti-Fas-
mAb as assesed by MTT assay as described in ‘Material and Methods’.
Difference in viability is matched to the viability of the corresponding
untreated cell line. Values expressed as mean ± SD. Statistical difference
between RT4/RT112 and T24/TCCSUP after 48 and 72 h (P < 0.05) 
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Figure 6 Comparison of apoptosis induction in bladder cancer cells after 24
and 48 h of incubation time with 1 mg ml–1 inducing anti-Fas-mAb as
assessed by FACS analysis after Annexin-V/PI staining. All cell lines
demonstrated a spontaneous apoptotic rate of cells of <15%. Values
expressed as mean ± SD. *P < 0.01, #P < 0.05 
Table 1 sFas in cell culture supernatants from 103–107 cells were repeated
determined and analysed by specific ELISA as described in Materials and
Methods. Concentrations of sFas were determined by comparison with a
standard curve. Values are expressed as median and range 
TCC cell line sFas (U ml–1) 106 cells sFas (U ml–1) 107 cells 
RT112 3.1 (1.1–4.5) 5.1 (1.9–8.3) 
RT4 2.3 (1.3–5.2) 6.2 (2.4–9.1) 
T24 3.3 (1.9–5.5) 4.9 (2.1–7.9) 
TCCSUP 2.7 (1.3–4.7) 7.7 (2.6–8.5) Bladder cancer cells escape Fas-mediated apoptosis 1335
British Journal of Cancer (2001) 84(10), 1330–1338 © 2001 Cancer Research Campaign
As shown in Figure 7A–D, T24 cells induces apoptosis and cell
death in Jurkat cells. With increasing numbers of T24, the rate of
apoptotic Jurkat cells increased. At an T24/Jurkat-ratio of 10:1 up
to 41.9% apoptosis was seen in Jurkat, whereas in a 10:1
Jurkat/T24-ratio no apoptosis of Jurkat was found (Figure 7E). To
confirm, that Jurkat cell killing was mediated by Fas-ligand,
experiments with neutralizing anti-Fas-ligand antibody were
performed. Thereby, 10 mg ml–1 of the clone NOK-1 antibody was
added to the co-cultured cells. As shown Figure 7F, the rate of
apoptosis was significantly lower in cells treated with a Fas-ligand
blocking antibody. 
On the other hand, T24 cancer cells were not killed even by high
rates (1:10) of Jurkat (Figure 8). The effect of T24 cells on
activated PBMC was more pronounced. At a ratio of 1:1 a signifi-
cant increase in apoptosis (69.9%) could be observed compared to
the spontaneous apoptotic rate (15.9%), which could be blocked by
Fas-ligand antibody (Figure 9A–C). Again, the immune cells (acti-
vated PBMC) did not affect T24 viability significantly (Figure 9D).
The lower-grade malignant RT4, lacking Fas-ligand, were not
able to induce apoptosis in Jurkat or PBMC, but were also not
susceptible to high rates (10:1) of Fas-ligand expressing Jurkat or
PBMC cells (data not shown). 
DISCUSSION 
Mechanisms of resistance against Fas mediated cell killing have
been reported in different malignancies (Dhein et al, 1995; Natoli
et al, 1995; O’Connell et al, 1996; Strand et al, 1996; Niehans et al,
1997; Shiraki et al, 1997; Ding et al, 1998; Gratas et al, 1998;
Ungefroren et al, 1998; Bernstorff et al, 1999). To date, these
studies were performed without taking into consideration that the
biological response of immune escape mechanisms might depend
on malignant transformation of cancer cells. 
We now report that Fas, the receptor of Fas-ligand, is expressed
and shedded by human transitional bladder carcinoma cell lines
RT4, RT112, T24 and TCCSUP. Treatment of these cell lines with
agonistic anti-Fas antibody results in different apoptotic suscepti-
bility in grade 1 (RT4, RT112), grade 3 (T24) and grade 4
(TCCSUP) bladder cancer cell lines. Only the well differentiated
cell lines, RT4 and RT112, were sensitive to anti-Fas. We demon-
strate, that all cancer cell lines transcribe the Fas-ligand gene, but
only poorly differentiated cell lines accumulate substantial
amounts of Fas-ligand protein. In co-culture experiments we show
that poorly differentiated cells can induce apoptosis and cell death
in Jurkat cells and activated peripheral blood mononuclear cells.
The cell surface expression of Fas is prerequisite for an effective
Fas/Fas-ligand interaction between immune and malignant cells.
Lack of Fas receptor expression can be one mechanism of apop-
tosis resistance (Strand et al, 1996). Since Fas receptor expression
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is correlated with sensitivity towards Fas-ligand mediated apop-
tosis (Moers et al, 1999), the down-regulation or lack of Fas
receptor expression on cancer cells is one of the mechanisms of
immune escape. Finding Fas expression on all bladder cancer cell
lines could imply that those cell lines respond to Fas-mediated cell
death. However, cytotoxicity and apoptosis assays demonstrate
that in spite of Fas expression, poorly differentiated T24 and
TCCSUP cells are insensitive towards either recombinant Fas-
ligand or agonistic apoptosis-inducing monoclonal antibody
against Fas. Thus, the poorly differentiated cells seem to have
acquired resistance towards Fas-inducible apoptosis downstream
to the Fas-receptor. Decreased susceptibility or resistance to Fas-
mediated apoptosis has been reported previously in carcinoma of
the liver (Owen-Schaupp et al, 1995), colon (O’Connell et al,
1996) and pancreas (Ungefroren et al, 1998). It has been suggested
that cancer cells must be resistant to Fas-signalling not only to
escape a cytotoxic attack by Fas-ligand expressing T cells but also
to avoid fratricide by Fas-ligand carrying sister cancer cells
(Ungefroren et al, 1998). 
Several Fas signal-blocking factors or mechanisms may be
responsible for this phenomenon. The X-chromosome-linked-
inhibitor of apoptosis protein (XIAP) or survivin, a member of the
IAP gene family, can block apoptosis induction by Fas through
binding specifically to the terminal effector proteases caspase-3
and caspase-7 (Tamm et al, 1998; Yamaguchi et al, 1999). Other
factors that may influence Fas signalling include FLICE-inhibitory
proteins (FLIPs) (Irmler et al, 1997), bcl-2 influence on the intra-
cellular signalling pathways of Fas (Itoh et al, 1993; Weller et al,
1995) and various components of the ubiquitin-proteasome
complex (Wang and Lenardo, 1997), but their individual role in
cancer development is not yet clear. 
For measuring Fas-ligand expression on bladder cancer cells we
employed flow cytometry, immunoblotting and RT-PCR. In poorly
differentiated T24 and TCCSUP cell lines we were able to detect
marked Fas-ligand protein by flow cytometry and Western blot
analysis. In grade 1 RT4 and RT112 cells only minor expression of
Fas-ligand protein was found by flow cytometry and Western blot
failed to detect the full-length, membrane bound form of Fas-
ligand possibly because of metalloproteinase action (Ungefroren et
al, 1998; Powell et al, 1999; Gastman et al, 2000). Fas-ligand
mRNA expression was found in all bladder cancer cell lines by
performing RT-PCR. Therefore, Fas-ligand mRNA translation
and/or post-translational processing seems to be regulated differ-
entially in the cancer cell lines. The marked expression of Fas-
ligand protein in high-grade T24 and TCCSUP cell lines in
comparison to the minor expression in low-grade RT4 and RT112
cells suggests that malignant transformation to higher-grade
bladder cancer goes along with (post-)transcriptional events by
which Fas-ligand protein production and/or processing is posi-
tively supported. 
Our finding that T24 and SUP bladder cancer cells express Fas-
ligand protein led to co-culture experiments with Jurkat, as a
model of activated T cells, and with peripheral blood mononuclear
cells (PBMC) to test the functional properties of this molecule as
presented by the TCC. Our results show that T24 cells bearing Fas-
ligand can effectively kill Jurkat cells and activated PBMC
whereas Fas-ligand negative RT4 cells could not. This cell killing
is mediated by the Fas-ligand as shown in the experiments where
anti-Fas-ligand abrogates the functional property of the Fas-
ligand. Together, this suggests that high-grade malignant bladder
cancers may be more competent in adopting mechanisms of
immune escape than low-grade cancers. On the other hand, Jurkat
cells and PBMC, although expressing Fas-ligand themselves, did
not induce apoptosis in T24 cells which coincides with the T24
cell resistance to anti-Fas inducible apoptosis. However, Fas sensi-
tive RT4 cells showed no increase in cell death after co-culture
with Jurkat and activated PBMC cells. Although induction of
apoptosis was expected, repeated experiment did not show this
effect. The reason might be biological concentration and regula-
tion differences between apoptosis-inducing anti-Fas-mAb and the
Fas-ligand presented on activated immune cells. 
The production of soluble Fas and soluble Fas-ligand may add
to the immunosuppressive effects of tumours (Hahne et al, 1996)
and was tested in all bladder cancer cell lines. Finally, we were
able to demonstrate the production of soluble Fas (sFas) but not of
soluble Fas-ligand in all bladder cancer cell lines. The importance
of this finding for immune escape may be that sFas can antago-
nize/neutralize cell surface Fas-ligand of T cells and thus decrease
their anti-tumour cytotoxic activity (Mizutani et al, 1998).
Mizutani et al (1998) reported elevated sFas levels in the serum of
patients with bladder cancer and suggested an association of high
sFas levels with poor prognosis. 
Both sFas-ligand and sFas are released to the extracellular
milieu and may, beyond the local site of tumour establishment,
induce apoptosis in lymphocytes and Fas-expressing cells as well
as diminish immune cell function in potential metastatic sites, thus
facilitating tumour cell propagation (Mitsiades et al, 1998). In
another study, paraffin-embedded tissues from 37 patients with
TCC were analysed by immunohistochemistry to determine Fas
and Fas-ligand expression. Fas and Fas-ligand were detected on
the cell surface and cytoplasm of 92% of cases, but the expression
did not differ with the cytological grade of the TCC. The authors
suggest that Fas-ligand may contribute to the immune escape of
TCC by killing Fas-bearing lymphocytes and that co-expression of
Fas with Fas-ligand also suggests that TCC may have pathways
resistant to Fas-mediated autocrine cell suicide (Lee et al, 1999).
This observation supports the results of the present study. 
In a study by Muschen et al (1999) it was shown that breast
cancer cells have an inverse regulation of Fas-ligand and receptor
expression during dedifferentiation. In addition, tissue sections
showed apoptosis of tumour infiltrating lymphocytes and stromal
cell in close proximity to Fas-ligand expressing high-grade breast
cancer cells. 
Mizutani et al suggested that anti-tumor cytotoxic lymphocytes
can coexist with immunoresistant tumour cells. It was reasoned
that anti-tumor cytotoxic activity of lymphocytes may be revealed
only if the tumour cells are sensitized to killing. The authors inves-
tigated the effect of adriamycin (ADR) on the susceptibility of
freshly isolated bladder cancer cells to lysis by autologous non-
activated peripheral blood lymphocytes (PBL) and tumour-
infiltrating lymphocytes (TIL). It was observed that PBL and TIL
in patients with bladder cancer exhibited anti-tumor cytotoxic
properties, but these properties were not manifest due to develop-
ment or acquisition of tumour cell resistance. However, the resis-
tance of bladder cancer cells to killing by cytotoxic lymphocytes
was overcome if cancer cells were sensitized by subtoxic concen-
trations of ADR. These findings may suggest that treatment of
bladder cancer patients with low doses of ADR may sensitize the
cancer cells to killing by autologous circulating and tumour-
infiltrating lymphocytes (Mizutani et al, 1999). 
In summary, we demonstrated the expression of functional 
Fas-ligand on high-grade cancer cell lines and their resistance toBladder cancer cells escape Fas-mediated apoptosis 1337
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Fas-mediated apoptosis. Furthermore we displayed the production
of soluble Fas molecules in all bladder cancer cells. Bladder
cancer cells may take advantage of different mechanisms of
immune evasion and become more competent in avoiding immune
surveillance during transformation to higher-grade malignant
disease as found in this in vitro study. The understanding of these
multifactorial mechanisms that can determine cancer resistance
will hopefully contribute to new strategies in treatment. 
ACKNOWLEDGEMENTS 
This work was supported in part by a grant from the A von Krupp
and Bohlen-Halbach Stiftung, Essen, Germany. 
REFERENCES 
Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley A, Goodwin
RG, Smith CA, Ramsdell F and Lynch DH (1995) Fas ligand mediates
activation-induced cell death in human T lymphocytes. J Exp Med 181: 71–77 
Arase H, Arase N and Saito T (1995) Fas-mediated cytotoxicity by freshly isolated
natural killer cells. J Exp Med 181: 1235–1238 
Bamberger AM, Schulte HM, Thuneke I, Erdmann I, Bamberger CM and Asa SL
(1997) Expression of the apoptosis-inducing Fas ligand (FasL) in human first
and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol
Metab 82: 3173–3175 
Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper
M, Goedegebuure PS and Eberlein TJ (1999) Pancreatic cancer cells can evade
immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and
aberrant expression of functional Fas ligand. Surgery 125: 73–84 
Cascino I, Fiucci G, Papoff G and Ruberti G (1995) Three functional soluble forms
of the human apoptosis-inducing Fas-molecule are produced by alternative
splicing. J Immunol 154: 2706–2713 
Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ and Mountz JD
(1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas
molecule. Science 263: 1759–1762 
Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I and
Browning JL (1997) TWEAK, a new secreted ligand in the tumor necrosis
factor family that weakly induces apoptosis. J Biol Chem 272: 32401–32410 
Crowe DL, Boardman ML and Fong KS (1998) Anti-Fas antibody differentially
regulates apoptosis in Fas ligand resistant carcinoma lines via the caspase 3
family of cell death proteases but independently of bcl2 expression. Anticancer
Res 18: 3163–3170 
Dhein J, Walczak H, Bäumle D, Debatin KM and Krammer PH (1995) Autocrine T-
cell suicide mediated by APO-1/(FasCD95). Nature 373: 438–440 
Ding EX, Hizuta A, Morimoto Y, Tanida T, Hongo T, Ishii T, Yamano T, Fujiwara T,
Iwagaki H and Tanaka N (1998) Human colon cancer cells express the
functional Fas ligand. Res Commun Mol Pathol Pharmacol 101: 13–24 
Gastman BR, Yin XM, Johnson DE, Wieckowski E, Wang GO, Watkins SC and
Rabinovich H (2000) Fas ligand is expressed on human squamous cell
carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
Cancer Res 59: 5356–5364 
Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O,
Kleihues P and Ohgaki H (1997) Fas ligand expression in human glioblastoma
cell lines and primary astrocytic brain tumors. Brain Pathol 7: 863–869 
Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P and Ohgaki H (1998) Up-
regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression
in human esophageal cancer. Cancer Res 58: 2057–2062 
Griffith TS, Yu X, Herndon JM, Green DR and Ferguson TA (1996) CD95-induced
apoptosis of lymphocytes in an immune privileged site induces immunological
tolerance. Immunity 5: 7–16 
Gruss HJ (1996) Molecular, structural, and biological characteristics of the tumor
necrosis factor ligand superfamily. Int J Clin Lab Res 26: 143–159 
Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P,
Bornard T, Fontana A, Lienard D, Cerottini JC and Tschopp J (1996)
Melanoma cell expression of Fas (APO-1/CD95) ligand: Implication for tumor
immune escape. Science 274: 1363–1366 
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL,
Schroter M, Burns K, Mattmann C, Rimoldi D, French LE and Tschopp J
(1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:
190–195 
Itoh N, Tsujimoto Y and Nagata S (1993) Effect of bcl-2 on Fas-antigen mediated
cell death. J Immunol 151: 621–6227 
Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H
and Golstein P (1994) Fas and perforin pathways as major mechanisms of T
cell-mediated cytotoxcicity. Science 265: 528–530 
Kayagaki NA, Kawasaki T, Ebata H, Ohmoto S, Ikeda S, Yoshino K, Okumura K
and Yagita H (1995) Metalloproteinase-mediated release of human Fas ligand.
J Exp Med 182: 1777–1783 
Klas C, Debatin KM, Jonker RR and Krammer PH (1993) Activation interferes with
the APO-1 pathway in mature human T cells. Int Immunol 5: 625–630 
Lee SH, Lee JY, Park WS, Kim SY, Jang JJ and Yoo NJ (1999) Transitional
cell carcinoma expresses high levels of Fas ligand in vivo. BJU Int 83:
698–702 
Liu C, Cheng J and Mountz J (1995) Differential expression of human Fas mRNA
species upon peripheral blood mononuclear cell activation. J Biochem 310:
957–963 
Midis GP, Shen Y and Owen-Schaupp LB (1996) Elevated soluble Fas (sFas) in
nonhematopoetic human malignancy. Cancer Res 56: 3870–3874 
Mitsiades N, Poulaki V, Kotoula V, Leone A and Tsokos M (1998) Fas ligand is
present in tumors of the Ewing’s sarcoma family and is cleaved into a soluble
form by a metalloproteinase. Am J Pathol 153: 1947–1956 
Mizutani Y, Yoshida O and Bonavida B (1998) Prognostic significance of soluble
Fas in the serum of patients with bladder cancer. J Urol 160: 571–576 
Mizutani Y, Yoshida O and Miki T (1999) Adriamycin-mediated potentiation of
cytotoxicity against freshly isolated bladder cancer cells by autologous non-
activated peripheral blood lymphocytes and tumor infiltrating lymphocytes. J
Urol 62: 2170–2175 
Moers C, Warskulat U, Muschen M, Even J, Niederacher D, Josien R, Koldovsky U,
Beckmann MW and Haussinger D (1999) Regulation of CD95 (Fas/APO-1)
ligand and receptor expression in squamous cell carcinoma by interferon-g and
cisplatin. Int J Cancer 80: 564–572 
Muschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien
R, Beckmann MW and Haussinger D (1999) CD95 ligand expression in
dedifferentiated breast cancer. J Pathol 189: 378–386 
Nagata S (1997) Apoptosis by death factor. Cell 88: 355–365 
Nakamura S, Takeshima M, Nakamura Y, Ohtake S and Matsuda T (1997) Induction
of apoptosis in HL60 leukemic cells by anticancer drugs in combination with
anti-Fas monoclonal antibody. Anticancer Res 17: 173–179 
Natoli G, Ianni A, Costanzo A, De Petrillo G, Ilari I, Chirillo P, Balsano C and
Levero M (1995) Resistance to Fas-mediated apoptosis in human hepatoma
cells. Oncogene 10: 1157–1164 
Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR
and Kratzke RA (1997) Human lung carcinoma express Fas ligand. Cancer Res
57: 1007–1012 
O’Connell J, O’Sullivan GC, Collins JK and Shanahan F (1996) The Fas
counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas
ligand. J Exp Med 184: 1075–1082 
Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzaw A, Kasugai T, Kitamura
Y, Itoh N, Suda T and Nagata S (1993) Lethal effect of the anti-Fas-antibody in
mice. Nature 364: 806–809 
Owen-Schaub LB, Radinsky R, Kruzel E, Berry K and Yonehara S (1994) Anti-Fas
on non-hematopoetic tumors: levels of Fas/APO-1 and bcl-2 are not predicive
of biological responsiveness. Cancer Res 54: 1580–1586 
Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesener TG, and Bartos DP
(1995) Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis?
Cancer Lett 94: 1–8 
Powell WC, Fingleton B, Wilson CL, Boothby M and Matrisian LM (1999) The
metalloproteinase matrilysin proteolytically generates active soluble Fas ligand
and potentiates epithelial cell apoptosis. Curr Biol 9: 1441–1447 
Runic R, Lockwood CJ, Ma Y, Dipasquale B and Guller S (1996) Expression of Fas
ligand by human cytotrophoblasts: implications in placentation and fetal
survival. J Clin Endocrinol Metab 81: 3119–3122 
Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S and Peter ME (1998) Apoptosis
signaling by death receptors. Eur J Biochem 254: 439–459 
Shiraki K, Tsuji N, Shioda T, Isselbacher KJ and Takahashi H (1997) Expression of
Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl
Acad Sci USA 94: 620–625 
Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel
W, Krammer PH and Galle PR (1996) Lymphocyte apoptosis induced by CD95
(APO-1/Fas) ligand expressing tumor cells – A mechanism of immune
evasion? Nature Med 12: 1361–1366 
Suda T, Takahashi T, Golstein P and Nagata S (1993) Molecular cloning and
expression of the Fas-ligand, a novel member of the tumor necrosis factor
family. Cell 75: 1169–1178 1338 FGE Perabo et al 
British Journal of Cancer (2001) 84(10), 1330–1338 © 2001 Cancer Research Campaign
Suda T, Hashimoto H, Tanaka M, Ochi T and Nagata S (1997) Membrane Fas ligand
kills human peripheral blood T lymphocytes and soluble Fas ligand blocks the
killing. J Exp Med 186: 2045–2050 
Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC
(1998) IAP-family protein survivin inhibits caspase activity and apoptosis
induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:
5315–5320 
Tanaka M, Suda T, Takahashi T and Nagata S (1995) Expression of the functional
soluble form of human Fas ligand in activated lymphocytes. EMBO 14:
1129–1135 
Thilenius AR, Braun K and Russel JH (1997) Agonist antibody and Fas ligand
mediate different sensitivity to death in the signaling pathways of Fas and
cytoplasmic mutants. Eur J Immunol 27: 1108–1114 
Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B and
Kalthoff H (1998) Human pancreatic adenocarcinomas express Fas 
and Fas Ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 58:
1741–1749 
Von Reyher U, Sträter J, Kittstein W, Gschwendt M, Krammer PH and Möller P
(1998) Colon carcinoma cells use different mechanisms to escape CD95-
mediated apoptosis. Cancer Res 58: 526–534 
Wang J and Lenardo MJ (1997) Molecules involved in cell death and peripheral
tolerance. Curr Opin Immunol 9: 818–825 
Weller M, Malipiero U, Aguzzi A, Reed JC and Fontana A (1995) Protooncogene
bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of
human malignant glioma cells and conferes resistance to chemotherapeutic
drugs and therapeutic irradiation. J Clin Invest 95: 2633–2643 
Yamaguchi K, Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K, Ueno N,
Nishida E, Shibuya H and Matsumoto K (1999) XIAP, a cellular member of the
inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the
BMP signaling pathway. EMBO 18: 179–187 